Isracann Biosciences

Israel’s First Pure-Play Cannabis Company

Overview

Isracann Biosciences Inc. (CSE:IPOT) is an Israeli-based cannabis company focused on becoming a premier low-cost cannabis producer. To this aim, the company is developing its fully-funded 230,000-square-foot cultivation facility near Tel Aviv, Israel. Isracann plans to target the undersupplied domestic and European markets with high-quality medical cannabis products manufactured at its facility.

The facility is being built to ISL and EU-GMP standards, and the company is applying for IMC-GAP and GSP certification, which allows Isracann to export its products and brands into Europe. The building is also designed to be a hybrid greenhouse, allowing the company to capitalize on Israel’s ideal climate and growing conditions.

Isracann’s Company Highlights

  • Isracann is focused on becoming a premier low-cost cannabis producer in Israel and the EU.
  • The European cannabis market is expected to be worth 123 billion euros by 2028.
  • Isracann is developing a fully-funded 230,000-square-foot cultivation facility near Tel Aviv.
  • Once complete, the facility can produce up to 23,500 kilograms of cannabis annually.